FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382806779> ?p ?o ?g. }

• W4382806779 endingPage "S173" @default.
• W4382806779 startingPage "S173" @default.
• W4382806779 abstract "The modified schedule of FOLFOXIRI (mFOLFOXIRI) in combination with an anti-EGFR agent showed a manageable safety profile and remarkable activity in RAS wild-type (wt) metastatic colorectal cancer (mCRC). The association of an active cytotoxic regimen with cetuximab (cet) may increase the exposure of tumour-associated neoantigens and induce immunogenic cell death and antibody-dependent cell-mediated cytotoxicity thus enabling the effect of immune checkpoint inhibitors. The AVETRIC study aimed at exploring the efficacy and safety of first-line mFOLFOXIRI plus cet and avelumab (ave) in RAS wt mCRC patients (pts). AVETRIC is a prospective, open label, multicenter, phase II, single arm trial in which initially unresectable and previously untreated RAS wt mCRC pts received mFOLFOXIRI (irinotecan 150 mg/sqm, oxaliplatin 85 mg/sqm, folinate 200 mg/sqm leucovorin [LV], and 5-fluorouracil [5FU] 2400 mg/sqm) plus cet (500 mg/sqm) and ave (800 mg) every 2 weeks up to 12 cycles followed by maintenance with 5FU/LV plus cet and ave until disease progression. A safety run-in phase including the first 6 enrolled pts was planned. Due to the occurrence of grade 3-4 diarrhoea in 2 (33%) pts, the protocol study was amended to reduce the irinotecan dose to 130 mg/sqm. Primary endpoint was Progression Free Survival (PFS). Fifty-eight pts were needed to detect an increase in median PFS (mPFS) from 10.0 to 19.4 months (mos), setting one-sided α and β errors at 0.05 and 0.10, respectively. The trial is registered at Clinicaltrial.gov, NCT04513951. Between Jun 2020 and Dec 2021, 62 pts were enrolled in 16 Italian centres. Main pts' characteristics were: median age 56 yrs, ECOG PS 0 87%, synchronous metastases 94%, liver-only disease 42%, left-sided primary tumour 89%; all pts had BRAF wt and proficient MMR (pMMR) tumours. The primary endpoint was met. At a median follow-up of 16.0 months, 39 (63%) events were recorded and mPFS was 14.1 months (90% CI 12.0-16.7, Brookmeyer-Crowley test p < 0.001). Response rate and disease control rate were 82% and 98%, respectively, and R0 resection rate was 21% (27% in liver-only subgroup). Early tumour shrinkage was achieved in 74% pts and median deepness of response was 56%. In pts treated after study amendment (n=56), main grade 3-4 adverse events were neutropenia (27%), diarrhoea (27%), skin rash (14%), asthenia (14%), nausea (11%), stomatitis (7%), febrile neutropenia (2%). Grade 3-4 immune-related adverse events occurred in 6% of pts. Overall survival results are still immature. AVETRIC study met its primary endpoint, showing that combining mFOLFOXIRI plus cet and ave achieves promising results in terms of PFS as well as response rate, in pts with pMMR RAS and BRAF wt mCRC. Translational analyses to evaluate the impact of immune-related biomarkers are ongoing." @default.
• W4382806779 created "2023-07-02" @default.
• W4382806779 creator A5001689204 @default.
• W4382806779 creator A5004626743 @default.
• W4382806779 creator A5006355590 @default.
• W4382806779 creator A5012233597 @default.
• W4382806779 creator A5022734154 @default.
• W4382806779 creator A5028325185 @default.
• W4382806779 creator A5034035272 @default.
• W4382806779 creator A5058514609 @default.
• W4382806779 creator A5059514389 @default.
• W4382806779 creator A5063093846 @default.
• W4382806779 creator A5066696741 @default.
• W4382806779 creator A5072503801 @default.
• W4382806779 creator A5074749942 @default.
• W4382806779 creator A5079150333 @default.
• W4382806779 creator A5079437223 @default.
• W4382806779 creator A5080776095 @default.
• W4382806779 creator A5080826945 @default.
• W4382806779 creator A5081985776 @default.
• W4382806779 creator A5086579812 @default.
• W4382806779 creator A5091765229 @default.
• W4382806779 date "2023-06-01" @default.
• W4382806779 modified "2023-10-03" @default.
• W4382806779 title "SO-27 Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO" @default.
• W4382806779 doi "https://doi.org/10.1016/j.annonc.2023.04.499" @default.
• W4382806779 hasPublicationYear "2023" @default.
• W4382806779 type Work @default.
• W4382806779 citedByCount "0" @default.
• W4382806779 crossrefType "journal-article" @default.
• W4382806779 hasAuthorship W4382806779A5001689204 @default.
• W4382806779 hasAuthorship W4382806779A5004626743 @default.
• W4382806779 hasAuthorship W4382806779A5006355590 @default.
• W4382806779 hasAuthorship W4382806779A5012233597 @default.
• W4382806779 hasAuthorship W4382806779A5022734154 @default.
• W4382806779 hasAuthorship W4382806779A5028325185 @default.
• W4382806779 hasAuthorship W4382806779A5034035272 @default.
• W4382806779 hasAuthorship W4382806779A5058514609 @default.
• W4382806779 hasAuthorship W4382806779A5059514389 @default.
• W4382806779 hasAuthorship W4382806779A5063093846 @default.
• W4382806779 hasAuthorship W4382806779A5066696741 @default.
• W4382806779 hasAuthorship W4382806779A5072503801 @default.
• W4382806779 hasAuthorship W4382806779A5074749942 @default.
• W4382806779 hasAuthorship W4382806779A5079150333 @default.
• W4382806779 hasAuthorship W4382806779A5079437223 @default.
• W4382806779 hasAuthorship W4382806779A5080776095 @default.
• W4382806779 hasAuthorship W4382806779A5080826945 @default.
• W4382806779 hasAuthorship W4382806779A5081985776 @default.
• W4382806779 hasAuthorship W4382806779A5086579812 @default.
• W4382806779 hasAuthorship W4382806779A5091765229 @default.
• W4382806779 hasBestOaLocation W43828067791 @default.
• W4382806779 hasConcept C121608353 @default.
• W4382806779 hasConcept C126322002 @default.
• W4382806779 hasConcept C141071460 @default.
• W4382806779 hasConcept C143998085 @default.
• W4382806779 hasConcept C203092338 @default.
• W4382806779 hasConcept C2776694085 @default.
• W4382806779 hasConcept C2776705615 @default.
• W4382806779 hasConcept C2779998722 @default.
• W4382806779 hasConcept C2780259306 @default.
• W4382806779 hasConcept C2780739268 @default.
• W4382806779 hasConcept C2780962732 @default.
• W4382806779 hasConcept C2781413609 @default.
• W4382806779 hasConcept C31760486 @default.
• W4382806779 hasConcept C526805850 @default.
• W4382806779 hasConcept C535046627 @default.
• W4382806779 hasConcept C71924100 @default.
• W4382806779 hasConcept C90924648 @default.
• W4382806779 hasConceptScore W4382806779C121608353 @default.
• W4382806779 hasConceptScore W4382806779C126322002 @default.
• W4382806779 hasConceptScore W4382806779C141071460 @default.
• W4382806779 hasConceptScore W4382806779C143998085 @default.
• W4382806779 hasConceptScore W4382806779C203092338 @default.
• W4382806779 hasConceptScore W4382806779C2776694085 @default.
• W4382806779 hasConceptScore W4382806779C2776705615 @default.
• W4382806779 hasConceptScore W4382806779C2779998722 @default.
• W4382806779 hasConceptScore W4382806779C2780259306 @default.
• W4382806779 hasConceptScore W4382806779C2780739268 @default.
• W4382806779 hasConceptScore W4382806779C2780962732 @default.
• W4382806779 hasConceptScore W4382806779C2781413609 @default.
• W4382806779 hasConceptScore W4382806779C31760486 @default.
• W4382806779 hasConceptScore W4382806779C526805850 @default.
• W4382806779 hasConceptScore W4382806779C535046627 @default.
• W4382806779 hasConceptScore W4382806779C71924100 @default.
• W4382806779 hasConceptScore W4382806779C90924648 @default.
• W4382806779 hasLocation W43828067791 @default.
• W4382806779 hasOpenAccess W4382806779 @default.
• W4382806779 hasPrimaryLocation W43828067791 @default.
• W4382806779 hasRelatedWork W1958805062 @default.
• W4382806779 hasRelatedWork W2010928484 @default.
• W4382806779 hasRelatedWork W2014795358 @default.
• W4382806779 hasRelatedWork W2037724349 @default.
• W4382806779 hasRelatedWork W2058385450 @default.
• W4382806779 hasRelatedWork W2510242944 @default.
• W4382806779 hasRelatedWork W2617055067 @default.
• W4382806779 hasRelatedWork W3004551912 @default.
• W4382806779 hasRelatedWork W3125127244 @default.
• W4382806779 hasRelatedWork W4379282188 @default.

• next